Small trial of Bemdaneprocel, which aims to replace dopamine-producing neurons, raises hope for treatment
Scientists have reported early success in a trial of an experimental cell therapy for Parkinson’s disease, raising hope for patients.
Bemdaneprocel therapy is at an early stage, and the year-long trial involved just 12 patients, but the positive outcome is viewed as significant after decades of setbacks in the hunt for an effective treatment. Developed by BlueRock therapeutics, a subsidiary of the pharmaceutical company Bayer, it was shown to be safe and the data gave a tantalising suggestion that patients may have benefited.
About Author
More Stories
Scientists record seismic tremors from title-clinching Liverpool win over Spurs
Measles outbreak: how contagious is it and what are the symptoms?
Ronan the head-bobbing sea lion proves animals can keep a beat: ‘No human was better’